Roivant Sciences (ROIV) Non-Current Deferred Revenue (2022)
Roivant Sciences (ROIV) reported Non-Current Deffered Revenue of $11.9 million for fiscal Q2 2023 (quarter ended Sep 30, 2022), down 9.5% from the prior quarter.
Roivant Sciences (ROIV) Non-Current Deferred Revenue (2022) Analysis & Trends
At the end of FY2022 (ended Mar 31, 2022), Roivant Sciences posted Non-Current Deffered Revenue of $13.74 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn |
| 10 | Roivant Sciences | 29.81 Bn | 13.51 Bn | 31.77 Mn |
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 11.90 Mn |
| Jun 30, 2022 | 13.15 Mn |
| Mar 31, 2022 | 13.74 Mn |
Roivant Sciences Non-Current Deferred Revenue API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ROIV&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "non-current-deffered-revenue", "ticker": "ROIV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=ROIV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();